好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Spinal cord and infratentorial lesions in radiologically isolated syndrome are associated with decreased retinal ganglion cell/inner plexiform layer thickness
Multiple Sclerosis
S37 - MS Biomarkers (2:17 PM-2:28 PM)
008

The anterior visual pathway is a frequent site of subclinical involvement in MS, however the role of retinal imaging with optical coherence tomography (OCT) in assessing individuals with RIS remains largely unexplored.

To assess retinal layer thicknesses in radiologically isolated syndrome (RIS) and examine their associations with clinical features suggestive of increased risk for conversion to multiple sclerosis (MS).

 Thirty RIS subjects, fulfilling 2009 Okuda diagnostic criteria, and 60 age- and sex-matched healthy controls (HC) underwent retinal imaging with spectral-domain OCT. Retinal layer thicknesses were derived utilizing a validated automated segmentation algorithm.

Overall, retinal layer thicknesses did not differ between RIS and HC. However, RIS subjects with spinal cord (SC) lesions had lower ganglion cell + inner plexiform layer (GCIP) thickness compared to HC (-4.41μm; 95% CI -7.61 to -1.20μm; p=0.007) and RIS without SC lesions (-3.53μm; 95% CI -6.93 to -0.14μm; p=0.041). Similarly, RIS subjects with infratentorial (IT) brain lesions had lower GCIP thickness compared to HC (-4.07μm; 95% CI -6.33 to -1.82μm; p<0.001) and RIS without IT lesions (-3.49μm; 95% CI -6.62 to -0.35μm; p=0.029).  Multivariate analyses revealed that the presence of SC and IT lesions were independently associated with lower GCIP thickness in RIS (p=0.04 and p=0.03 respectively). Other patient characteristics, including sex, abnormal cerebrospinal fluid and presence of gadolinium-enhancing or juxtacortical lesions, were not associated with retinal layer thicknesses.

The presence of SC or IT lesions in RIS, proposed risk factors for conversion to MS, may be associated with retinal neuro-axonal loss, potentially supporting the presence of more disseminated disease in those RIS subjects. Longitudinal studies of larger cohorts of RIS subjects are necessary to confirm these findings and to evaluate the potential prognostic value of decreased GCIP thickness for conversion to MS.

Authors/Disclosures
Angeliki Filippatou, MD (Johns Hopkins University School of Medicine)
PRESENTER
Dr. Filippatou has nothing to disclose.
Thomas J. Shoemaker, MD (Rush University Medical Center) Dr. Shoemaker has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. Dr. Shoemaker has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AMGEN. Dr. Shoemaker has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for EMD Serono.
Megan E. Esch, MD (Geisinger Medical Center) Dr. Esch has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Esch has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Esch has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. Esch has received research support from PCORI.
No disclosure on file
Natalia Gonzalez Caldito, MD (home) Dr. Gonzalez Caldito has nothing to disclose.
Jerry Prince No disclosure on file
Ellen M. Mowry, MD, FAAN (Johns Hopkins University) Dr. Mowry has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BeCareLink, LLC. The institution of Dr. Mowry has received research support from Biogen. The institution of Dr. Mowry has received research support from Genentech. Dr. Mowry has received publishing royalties from a publication relating to health care.
Peter A. Calabresi, MD, FAAN (Johns Hopkins University) Dr. Calabresi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Calabresi has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. Dr. Calabresi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Idorsia. An immediate family member of Dr. Calabresi has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MyMD. Dr. Calabresi has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Myelin Repair Foundation. The institution of Dr. Calabresi has received research support from Genentech. Dr. Calabresi has received publishing royalties from a publication relating to health care. Dr. Calabresi has received personal compensation in the range of $500-$4,999 for serving as a Study Section Member with NIH. Dr. Calabresi has received personal compensation in the range of $500-$4,999 for serving as a Grant reveiwer with Myelin Repair Foundation. Dr. Calabresi has received personal compensation in the range of $500-$4,999 for serving as a Speaker for CME with NYAS. Dr. Calabresi has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Academic CME.
Shiv Saidha, MD (Johns Hopkins) Dr. Saidha has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ReWind Therapeutics. Dr. Saidha has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Saidha has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Saidha has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Clene Pharmaceuticals. Dr. Saidha has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Saidha has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Saidha has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Saidha has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Multiple Sclerosis Journal ETC. Dr. Saidha has stock in June Brain. Dr. Saidha has stock in Lapix Therapeutics. The institution of Dr. Saidha has received research support from Biogen. The institution of Dr. Saidha has received research support from Genentech. The institution of Dr. Saidha has received research support from Novartis. The institution of Dr. Saidha has received research support from Lapix Therapeutics. The institution of Dr. Saidha has received research support from Novartis.
Elias S. Sotirchos, MD (Johns Hopkins University) Dr. Sotirchos has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Sotirchos has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Sotirchos has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Sotirchos has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. The institution of Dr. Sotirchos has received research support from National Institutes of Health. The institution of Dr. Sotirchos has received research support from National Multiple Sclerosis Society. The institution of Dr. Sotirchos has received research support from Sumaira Foundation. The institution of Dr. Sotirchos has received research support from Genentech. The institution of Dr. Sotirchos has received research support from UCB. The institution of Dr. Sotirchos has received research support from Astoria Biologica. The institution of Dr. Sotirchos has received research support from Ad Scientiam. The institution of Dr. Sotirchos has received research support from Alexion. The institution of Dr. Sotirchos has received research support from Corevitas. Dr. Sotirchos has received personal compensation in the range of $500-$4,999 for serving as a Ad Hoc Reviewer with National Institutes of Health.